Madrigal Pharmaceuticals is part of the healthcare sector and is part of the biotechnology industry. The company CEO is Paul A. Friedman. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis NASH.



Previous Intraday Performance:

The MDGL shares had a previous change of 3.23% which opened at 95.51 and closed at 96.77. It moved to an intraday high of 98.48 and a low of 93.16.

SeekingAlpha:  Madrigal, Galmed, And Galectin In Phase 3 NASH: The Need For Therapeutic Diversity

Historical Performance:

Over the last five trading days, MDGL shares returned 1.77% and in the past 30 trading days it returned -11.48%. Over three months, it changed -30.22%. In one year it has changed -64.58% and within that year its 52 week high was 325.98 and its 52 week low was 90.00. MDGL stock is 7.52% above its 52 week low.

Our calculations result in a 200 day moving average of 148.44 and a 50 day moving average of 111.88. Right now, MDGL stock is trading -34.81% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Madrigal, Galmed, And Galectin In Phase 3 NASH: The Need For Therapeutic Diversity

Liquidity:

The company has a market cap of $1.5b with 15.4m shares outstanding and a float of 6.7m shares. Trading volume was 312,891 shares and has experienced an average volume of 153,312 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Madrigal Pharmaceuticals was -2.22 which ended on 31st of December 2018. Based on 6 analyst estimates, the consensus EPS for the next quarter is -0.91.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-08-2019: -0.98
4thQtr 2018Reported 02-27-2019: -0.75
3rdQtr 2018Reported 11-06-2018: -0.56
2ndQtr 2018Reported 08-07-2018: -0.45
1stQtr 2018Reported 05-08-2018: -0.45

The long-term trend of the EPS is an important number as it indicates the present value of Madrigal Pharmaceuticals.

Indicators Also to Watch:

Based on the latest filings, there is 80.80% of institutional ownership.



The beta was calculated to be 1.20.

SeekingAlpha:  Standing At The Edge Of The Abyss

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -12.53% and price-to-book is 3.08.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here